{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:20:15Z","timestamp":1763389215652},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The aim of this article is to review the current recommendations for the diagnosis and treatment of invasive fungal infection in the ICU setting and to explore whether there are standards of care for this patient population. The text focuses mainly on the two most common invasive fungal diseases that afflict non-neutropenic patients: candidaemia and invasive candidosis (IC), and invasive pulmonary aspergillosis (IPA).<\/jats:p>","DOI":"10.1093\/jac\/dkz038","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T20:50:37Z","timestamp":1548881437000},"page":"ii9-ii15","source":"Crossref","is-referenced-by-count":15,"title":["Defining standards of CARE for invasive fungal diseases in the ICU"],"prefix":"10.1093","volume":"74","author":[{"given":"Manuel","family":"Cuenca-Estrella","sequence":"first","affiliation":[{"name":"Instituto de Salud Carlos III, Ctra. Majadahonda-Pozuelo Km 2, Majadahonda, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel H","family":"Kett","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine at the University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost","family":"Wauters","sequence":"additional","affiliation":[{"name":"Clinical Department of General Internal Medicine, Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,3,23]]},"reference":[{"key":"2020071623431737700_dkz038-B1","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00134-017-4731-2","article-title":"Intensive care medicine research agenda on invasive fungal infection in critically ill patients","volume":"43","author":"Bassetti","year":"2017","journal-title":"Intensive Care Med"},{"key":"2020071623431737700_dkz038-B2","doi-asserted-by":"crossref","first-page":"O245","DOI":"10.1111\/1469-0691.12380","article-title":"Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain","volume":"20","author":"Puig-Asensio","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2020071623431737700_dkz038-B3","doi-asserted-by":"crossref","first-page":"672.e1","DOI":"10.1016\/j.cmi.2017.01.014","article-title":"Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance","volume":"23","author":"Fern\u00e1ndez-Ruiz","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2020071623431737700_dkz038-B4","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dkx028","article-title":"Changes in the epidemiological landscape of invasive mould infections and disease","volume":"72 Suppl 1","author":"Lass-Fl\u00f6rl","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020071623431737700_dkz038-B5","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1128\/AAC.00383-13","article-title":"Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study)","volume":"57","author":"Alastruey-Izquierdo","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071623431737700_dkz038-B6","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/CCM.0000000000000221","article-title":"Impact of therapeutic strategies on the prognosis of candidemia in the ICU","volume":"42","author":"Puig-Asensio","year":"2014","journal-title":"Crit Care Med"},{"key":"2020071623431737700_dkz038-B7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18 Suppl 7","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2020071623431737700_dkz038-B8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/cid\/civ1194","article-title":"Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020071623431737700_dkz038-B9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1469-0691.12038","article-title":"ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures","volume":"18 Suppl 7","author":"Cuenca-Estrella","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2020071623431737700_dkz038-B10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-1-4939-3052-4_16","article-title":"Diagnostic methods for detection of blood-borne candidiasis","volume":"1356","author":"Clancy","year":"2016","journal-title":"Methods Mol Biol"},{"key":"2020071623431737700_dkz038-B11","doi-asserted-by":"crossref","first-page":"51.","DOI":"10.3389\/fmicb.2018.00051","article-title":"Oligonucleotide array and VITEK matrix-assisted laser desorption ionization-time of flight mass spectrometry in species identification of blood yeast isolates","volume":"9","author":"Li","year":"2018","journal-title":"Front Microbiol"},{"key":"2020071623431737700_dkz038-B12","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1128\/AAC.02155-13","article-title":"Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011","volume":"58","author":"Guinea","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071623431737700_dkz038-B13","doi-asserted-by":"crossref","first-page":"149.","DOI":"10.1186\/s13054-016-1324-3","article-title":"Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions","volume":"20","author":"Le\u00f3n","year":"2016","journal-title":"Crit Care"},{"key":"2020071623431737700_dkz038-B14","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020071623431737700_dkz038-B15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1128\/JCM.01602-10","article-title":"PCR diagnosis of invasive candidiasis: systematic review and meta-analysis","volume":"49","author":"Avni","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2020071623431737700_dkz038-B16","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1093\/jac\/dku225","article-title":"Clinical validation of a multiplex real-time PCR assay for detection of invasive candidiasis in intensive care unit patients","volume":"69","author":"Fort\u00fan","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2020071623431737700_dkz038-B17","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1128\/JCM.00496-17","article-title":"Performance of a quantitative PCR-based assay and \u03b2-d-glucan detection for diagnosis of invasive candidiasis in very-low-birth-weight preterm neonatal patients (CANDINEO Study)","volume":"55","author":"Ramos","year":"2017","journal-title":"J Clin Microbiol"},{"key":"2020071623431737700_dkz038-B18","doi-asserted-by":"crossref","first-page":"e01756","DOI":"10.1128\/JCM.01756-17","article-title":"The efficacy of T2 magnetic resonance assay in monitoring candidemia after the initiation of antifungal therapy: the Serial Therapeutic and Antifungal Monitoring Protocol (STAMP) trial","volume":"56","author":"Mylonakis","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2020071623431737700_dkz038-B19","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/cid\/cix1095","article-title":"Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): a prospective, multicenter study of the T2 Candida panel","volume":"66","author":"Clancy","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020071623431737700_dkz038-B20","doi-asserted-by":"crossref","first-page":"i15","DOI":"10.1093\/jac\/dkq438","article-title":"Detection and investigation of invasive mould disease","volume":"66 Suppl 1","author":"Cuenca-Estrella","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2020071623431737700_dkz038-B21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24 Suppl 1","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2020071623431737700_dkz038-B22","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1128\/JCM.00905-15","article-title":"Clinical performance of Aspergillus PCR for testing serum and plasma: a study by the European Aspergillus PCR Initiative","volume":"53","author":"White","year":"2015","journal-title":"J Clin Microbiol"},{"key":"2020071623431737700_dkz038-B23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/cid\/ciu833","article-title":"Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial","volume":"60","author":"Aguado","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020071623431737700_dkz038-B24","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"2020071623431737700_dkz038-B25","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1164\/rccm.200812-1912OC","article-title":"Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study","volume":"180","author":"Ferrer","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2020071623431737700_dkz038-B26","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/CCM.0b013e3181cb0ddf","article-title":"Bundled care for septic shock: an analysis of clinical trials","volume":"38","author":"Barochia","year":"2010","journal-title":"Crit Care Med"},{"key":"2020071623431737700_dkz038-B27","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","article-title":"Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality","volume":"49","author":"Morrell","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071623431737700_dkz038-B28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020071623431737700_dkz038-B29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/jac\/dkm212","article-title":"Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections","volume":"60","author":"Parkins","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2020071623431737700_dkz038-B30","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1086\/374850","article-title":"A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects","volume":"36","author":"Rex","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020071623431737700_dkz038-B31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1086\/514504","article-title":"International conference for the development of a consensus on the management and prevention of severe Candida infections","volume":"25","author":"Edwards","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2020071623431737700_dkz038-B32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1086\/380796","article-title":"Guidelines for treatment of candidiasis","volume":"38","author":"Pappas","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020071623431737700_dkz038-B33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10096-002-0730-4","article-title":"Treatment of severe Candida infections in high-risk patients in Germany: consensus formed by a panel of interdisciplinary investigators","volume":"21","author":"Buchner","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020071623431737700_dkz038-B34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020071623431737700_dkz038-B35","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","article-title":"Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial","volume":"366","author":"Kullberg","year":"2005","journal-title":"Lancet"},{"key":"2020071623431737700_dkz038-B36","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"2020071623431737700_dkz038-B37","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"2020071623431737700_dkz038-B38","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. [Erratum appears in Clin Infect Dis 2008; 47: 302]","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020071623431737700_dkz038-B39","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF01726360","article-title":"Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group","volume":"16","author":"Phillips","year":"1997","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020071623431737700_dkz038-B40","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"2020071623431737700_dkz038-B41","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute","volume":"331","author":"Rex","year":"1994","journal-title":"N Engl J Med"},{"key":"2020071623431737700_dkz038-B42","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00134-014-3400-y","article-title":"Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. [Erratum appears in Intensive Care Med 2014; 40: 1974]","volume":"40","author":"Colombo","year":"2014","journal-title":"Intensive Care Med"},{"key":"2020071623431737700_dkz038-B43","doi-asserted-by":"crossref","first-page":"e0125149.","DOI":"10.1371\/journal.pone.0125149","article-title":"The effect on mortality of fluconazole or echinocandins treatment in candidemia in internal medicine wards [corrected]. [Erratum appears in PLoS One 2015; 10: e0131264]","volume":"10","author":"De Rosa","year":"2015","journal-title":"PLoS One"},{"key":"2020071623431737700_dkz038-B44","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/jac\/dks482","article-title":"Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study","volume":"68","author":"Eschenauer","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2020071623431737700_dkz038-B45","doi-asserted-by":"crossref","first-page":"37.","DOI":"10.1186\/1471-2253-13-37","article-title":"Candidemia in the critically ill: initial therapy and outcome in mechanically ventilated patients","volume":"13","author":"Ferrada","year":"2013","journal-title":"BMC Anesthesiol"},{"key":"2020071623431737700_dkz038-B46","doi-asserted-by":"crossref","first-page":"733.e1.","DOI":"10.1016\/j.cmi.2016.05.008","article-title":"Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort","volume":"22","author":"Lopez-Cortes","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2020071623431737700_dkz038-B47","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00134-014-3408-3","article-title":"Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002\u20132010)","volume":"40","author":"Lortholary","year":"2014","journal-title":"Intensive Care Med"},{"key":"2020071623431737700_dkz038-B48","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10096-015-2527-2","article-title":"Initial antifungal strategy does not correlate with mortality in patients with candidemia","volume":"35","author":"Murri","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020071623431737700_dkz038-B49","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.diagmicrobio.2007.06.008","article-title":"Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections","volume":"59","author":"Horn","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020071623431737700_dkz038-B50","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10096-007-0383-4","article-title":"Use of the PATH Alliance database to measure adherence to IDSA guidelines for the therapy of candidemia","volume":"26","author":"Horn","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020071623431737700_dkz038-B51","doi-asserted-by":"crossref","first-page":"83","DOI":"10.7326\/0003-4819-149-2-200807150-00004","article-title":"Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial","volume":"149","author":"Schuster","year":"2008","journal-title":"Ann Intern Med"},{"key":"2020071623431737700_dkz038-B52","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/cid\/ciu074","article-title":"MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting","volume":"58","author":"Ostrosky-Zeichner","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020071623431737700_dkz038-B53","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jama.2016.14655","article-title":"Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure: the EMPIRICUS randomized clinical trial","volume":"316","author":"Timsit","year":"2016","journal-title":"JAMA"},{"key":"2020071623431737700_dkz038-B54","doi-asserted-by":"crossref","first-page":"R253.","DOI":"10.1186\/cc10514","article-title":"Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis","volume":"15","author":"Kett","year":"2011","journal-title":"Crit Care"},{"key":"2020071623431737700_dkz038-B55","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","article-title":"Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials","volume":"54","author":"Andes","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020071623431737700_dkz038-B56","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/505870","article-title":". Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey","volume":"43","author":"Cornillet","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020071623431737700_dkz038-B57","doi-asserted-by":"crossref","first-page":"421.","DOI":"10.1186\/s13054-015-1140-1","article-title":"Putative invasive pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary disease: a matched cohort study","volume":"19","author":"Delsuc","year":"2015","journal-title":"Crit Care"},{"key":"2020071623431737700_dkz038-B58","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1439-0507.2011.02044.x","article-title":"Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006\u20132008)","volume":"55","author":"Tortorano","year":"2012","journal-title":"Mycoses"},{"key":"2020071623431737700_dkz038-B59","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/QCO.0000000000000043","article-title":"Approach to invasive pulmonary aspergillosis in critically ill patients","volume":"27","author":"Koulenti","year":"2014","journal-title":"Curr Opin Infect Dis"},{"key":"2020071623431737700_dkz038-B60","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020071623431737700_dkz038-B61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/1469-0691.12660","article-title":"Invasive fungal infections in solid organ transplant recipients","volume":"20 Suppl 7","author":"Gavalda","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2020071623431737700_dkz038-B62","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/lt.24032","article-title":"Invasive aspergillosis in liver transplant recipients: epidemiology, clinical characteristics, treatment, and outcomes in 116 cases","volume":"21","author":"Barchiesi","year":"2015","journal-title":"Liver Transpl"},{"key":"2020071623431737700_dkz038-B63","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/lt.21099","article-title":"Risk factors for invasive aspergillosis in living donor liver transplant recipients","volume":"13","author":"Osawa","year":"2007","journal-title":"Liver Transpl"},{"key":"2020071623431737700_dkz038-B64","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.resinv.2015.08.005","article-title":"Invasive pulmonary aspergillosis in organ transplants\u2014focus on lung transplants","volume":"54","author":"Geltner","year":"2015","journal-title":"Respir Investig"},{"key":"2020071623431737700_dkz038-B65","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1128\/AAC.02226-12","article-title":"Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis","volume":"57","author":"Seyedmousavi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071623431737700_dkz038-B66","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020071623431737700_dkz038-B67","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/01.mcg.0000248018.08515.f9","article-title":"Infections in patients with end-stage liver disease","volume":"41","author":"Cheruvattath","year":"2007","journal-title":"J Clin Gastroenterol"},{"key":"2020071623431737700_dkz038-B68","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus","volume":"21\u201322","author":"Verweij","year":"2015","journal-title":"Drug Resist Updat"},{"key":"2020071623431737700_dkz038-B69","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1586\/eri.13.29","article-title":"Combination antifungal therapy for invasive fungal infections in children and adults","volume":"11","author":"Hatipoglu","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2020071623431737700_dkz038-B70","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"2020071623431737700_dkz038-B71","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/cid\/ciu581","article-title":"Antifungal combination therapy for invasive aspergillosis","volume":"59","author":"Mart\u00edn-Pe\u00f1a","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020071623431737700_dkz038-B72","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/cid\/cix198","article-title":"Pharmacodynamics of isavuconazole for invasive mold disease: role of galactomannan for real-time monitoring of therapeutic response","volume":"64","author":"Kovanda","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/Supplement_2\/ii9\/28223627\/dkz038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/Supplement_2\/ii9\/28223627\/dkz038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T13:17:09Z","timestamp":1594991829000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/Supplement_2\/ii9\/5420180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":72,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2019,3,23]]},"published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz038","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2019,3,1]]}}}